Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-throughput screening using genome-wide siRNA libraries.

Zicai Liang1

  • 1Center for Genomics and Bioinformatics, Karolinska Institutet, Stockholm, Sweden. Zicai.Liang@cgb.ki.se

Idrugs : the Investigational Drugs Journal
|October 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran).

Blood advances·2026
Same author

A potent GalNAc-siRNA drug, RBD1016, leads to sustained HBsAg reduction and seroconversion in mouse models of HBV infection.

Molecular therapy. Nucleic acids·2025
Same author

Inhibition of Factor XI Using RBD4059: A Novel GalNAc-siRNA With Potent and Durable Antithrombotic Effects.

JACC. Basic to translational science·2025
Same author

Author Correction: Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation.

Nature communications·2025
Same author

Publisher Correction to: ISIS 449884 Injection Add‑On to Metformin in Patients with Type 2 Diabetes: A Randomized, Double‑Blind, Placebo‑Controlled, Phase II Clinical Study.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2024
Same author

The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II study.

Diabetes, obesity & metabolism·2024

Small-interfering RNA (siRNA) technology silences protein production by degrading messenger RNA. Its potency and ease of use enable genome-wide functional screening in life science research.

Area of Science:

  • Molecular Biology
  • Genetics

Background:

  • Small-interfering RNA (siRNA) is a novel technology for gene silencing.
  • It functions by targeting specific messenger RNA (mRNA) for degradation, thereby inhibiting protein production.

Purpose of the Study:

  • To highlight the utility of siRNA technology in life science research.
  • To emphasize its role in enabling genome-wide functional screening.

Main Methods:

  • Utilizing siRNA to degrade target mRNA sequences.
  • Employing comprehensive siRNA libraries for genome-wide coverage.

Main Results:

  • Demonstrated high potency and ease of application of siRNA technology.
  • Facilitated broad implementation across various life science research areas.

Related Experiment Videos

  • Enabled high-throughput functional screening at a genome-wide scale.

    • Conclusions:

    • siRNA technology is a powerful tool for gene function studies.
    • Its advancements support large-scale genetic screens and research applications.